Use of dienogest over 53 weeks for the treatment of endometriosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the efficacy and adverse effects of Dienogest (DNG) over 53 weeks for the treatment of endometriosis. Methods: DNG was administered to 75 patients with endometriosis over a period of 53 weeks. Medical charts were retrospectively examined on the efficacy and side effects. Reduction rates of ovarian chocolate cyst, adenomyosis and changes in serum estradiol and cancer antigen 125 concentration were measured. Adverse effects, patient evaluation of their symptoms and willingness to continue taking DNG were assessed by a questionnaire. Results: The median duration of treatment was 87 weeks, with the longest follow‐up duration being 120 weeks. Ovarian chocolate cysts were initially reduced; however, upon cessation of DNG treatment, an increase in size was observed. Adenomyosis lesions were reduced to some extent after 53 weeks of DNG treatment. In terms of adverse events, more than 60% (61.3%, 46/75) of patients experienced atypical genital bleeding. However, this did not prove to be a cause of discontinuation. We ceased DNG treatment in two cases because of lower abdominal pain and shoulder discomfort. Conclusions: Long term DNG treatment beyond one year for endometriosis proved to be effective and safe. Ovarian chocolate cysts were markedly reduced by short‐term use of DNG, while a longer duration was required to reduce the size of adenomyosis. The decision regarding the choice of therapy lies with the individual clinician, considering a balance of efficacy with expense and adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 2×
“A number of studies conducted on the efficacy and tolerability of DNG show that its therapeutic effects on endometriosis are equivalent to those of GnRHa,with fewer hypo-estrogenic symptoms, such as hot flushes and decreased bone mineral density.(4,8,9) DNG is currently approved for the treatment of endometriosis in t…”
BackgroundCosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Cited by
Leonardo-Pinto, J. P., Benetti-Pinto, C. L., Cursino, K., & Yela, D. A. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.02.015 · Cited by 72
Muzii, L., Galati, G., Di Tucci, C., Di Feliciantonio, M., Perniola, G., Di Donato, V., Benedetti Panici, P., & Vignali, M. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640199 · Cited by 55
“reported a reduction in cyst diameter to 70% of the initial size after 3months of medical treatment with dienogest, and to 30% of initial size after 15months of treatment, in a series of 26 patients with ovarian endometriomas [14].”
BackgroundEffect of Dienogest therapy on the size of the endometrioma
Vignali, M., Belloni, G. M., Pietropaolo, G., Barbasetti Di Prun, A., Barbera, V., Angioni, S., & Pino, I. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1725965 · Cited by 50
Koshiba, A., Mori, T., Okimura, H., Akiyama, K., Kataoka, H., Takaoka, O., Ito, F., Matsushima, H., Kusuki, I., & Kitawaki, J. (2018) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.13725 · Cited by 46
Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H. (2018) · Reproductive Sciences · doi:10.1177/1933719118779733 · Cited by 44
Metadata
- Authors
- Sugimoto, K., Nagata, C., Hayashi, H., Yanagida, S., & Okamoto, A.
- Venue
- Journal of Obstetrics and Gynaecology Research
- Publisher
- Wiley
- Published
- 2015-09-14
- Volume
- 41
- Issue
- 12
- Pages
- 1921-1926
- ISSN
- 1341-8076 (ISSN-L)
- 1447-0756
- OpenAlex
- W2123519165
- Cited by
- 60
- References
- 2
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.